Gemcitabine
From Wikipedia, the free encyclopedia
Gemcitabine
|
|
Systematic (IUPAC) name | |
4-amino-1-[3,3-difluoro-4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl]- 1H-pyrimidin- 2-one | |
Identifiers | |
CAS number | 95058-81-4 |
ATC code | L01BC05 |
PubChem | 60750 |
DrugBank | APRD00201 |
Chemical data | |
Formula | C9H11F2N3O4 |
Mol. weight | 263.198 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | <10% |
Metabolism | ? |
Half life | Short infusions 32-94 minutes for long infusions 245-638 minutes |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | Oral, intravenous |
Gemcitabine is a nucleoside used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company.
[edit] Pharmacology
Chemically gemcitabine is a nucleoside in which the hydrogens on the 2' carbon of deoxycytidine are replaced by fluorides.
As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as new nucleosides cannot be attached to the "faulty" nucleoside, resulting in apoptosis (cellular "suicide").
[edit] Indications
Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, and breast cancer. It is being investigated for use in oesophageal cancer, and is used experimentally in lymphomas and various other tumor types.